Work

Is the Combination of Pembrolizumab and Regorafenib the Beginning of a New Era in the Treatment of Metastatic Colorectal Cancer?

Year: 2025

Type: article

Abstract: Colorectal cancer is one of the most common lethal cancers worldwide.In the treatment of metastatic colorectal cancer (mCRC), survival rates have increased due to advancements in cytotoxic chemotherapy and targeted agents.However, the optimal use and sequence of these agents in multistage treatment protocols remain uncertain.Regorafenib, a multikinase inhibitor with immunomodulatory features, has been found to enhance antitumor activity in patients with gastric cancer and mCRC when combined with immunotherapy.Additionally, regorafenib treatment offers a manageable safety profile.In this study, we present the case of a patient with microsatellite instability-high mCRC who achieved a complete response to combination treatment with regorafenib and pembrolizumab.This case report aims to contribute to the literature on this novel combination therapy and provide guidance to clinicians in treatment practices and management.

Source: Journal of Oncological Sciences

DOI: 10.37047/jos.galenos.2025.2025-3-23

Authors: Aslı GEÇGEL, Fatma P. AÇAR, Oğuzcan ÖZKAN, Erdem GÖKER

Institutions: Ege University, Ege Üniversitesi Tıp Fakültesi Hastanesi

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4413284474